Benzinga | Nov 4, 2021 09:30AM EDT

Cellectis Announces Release Of Abstracts At ASH Showcasing Updated Preliminary Clinical Data From BALLI-01 Study And First Preclinical Data From TALGlobin01

Cellectis S.A. (NASDAQ:CLLS, EURONEXT GROWTH: ALCLS))) (the "Company"), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, today announced the release of two abstracts, which were accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11-14, 2021. The Company will present updated preliminary clinical data from its BALLI-01 clinical trial in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), and preclinical data for TALGlobin01 for patients with HbSS Sickle Cell Disease (SCD).

"2021 has been a busy and productive year for Cellectis, with our proprietary clinical and preclinical programs making noteworthy progress. Cellectis is advancing one of the most robust allogeneic CAR-T pipelines and we are excited to share additional preliminary data from our BALLI-01 clinical trial, which is evaluating UCART22, in patients with relapsed and refractory B-cell acute lymphoblastic leukemia for whom there continues to be an urgent need for safe and effective treatments. We are also proud to disclose initial pre-clinical data from our .HEAL platform's product candidate, TALGlobin01, which demonstrates that TALEN(r) could be specific and efficient at correcting the mutated beta-globin gene, the underlying cause of sickle cell disease," said Carrie Brownstein, MD, Chief Medical Officer at Cellectis.